Edwards Lifesciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Edwards Lifesciences (NYSE:EW) First Quarter 2024 Results

Key Financial Results

• Revenue: US$1.60b (up 9.5% from 1Q 2023).

• Net income: US$351.9m (up 3.3% from 1Q 2023).

• Profit margin: 22% (down from 23% in 1Q 2023). The decrease in margin was driven by higher expenses.

• EPS: US$0.58 (up from US$0.56 in 1Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Edwards Lifesciences Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 7.2%.

Looking ahead, revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Edwards Lifesciences' balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.